Genprex, Inc. is a clinical-stage gene therapy company focused on developing potentially life-changing technologies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies options for large patient populations with cancer and diabetes who currently have limited treatment options. The firm works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company's lead product candidate, REQORSA (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. Genprex was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.